Medical experts have disagreed on the most appropriate COVID-19 vaccine for the country as the National Agency for Food, Drug Administration and Control (NAFDAC), yesterday, gave emergency use authorisation.
Onyebuchi Ezigbo in Abuja
The National Agency for Food and Drug Administration and Control (NAFDAC) has approved the emergency use of AstraZeneca as COVID-19 vaccine in Nigeria.
AstraZeneca, from India, is one of the two vaccines received by Nigeria and forwarded to NAFDAC for scientific study.
The other one, Sputnik, developed by Russia, is still being studied by the agency.
NAFDAC’s Director-General, Prof. Mojisola Adeyeye, at a press conference yesterday Abuja said the agency had evaluated the safety and efficacy of the vaccine for Nigerians.
She said the vaccine could be stored in two to eight degrees Centigrade, adding that three more vaccines are being evaluated.
COVID-19: NAFDAC approves AstraZeneca/Oxford vaccine for use in Nigeria vanguardngr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vanguardngr.com Daily Mail and Mail on Sunday newspapers.
The National Agency for Food and Drug Administration and Control has approved AstraZeneca COVID-19 vaccine for use in Nigeria NAFDAC in a press briefing said it got the dossier of the vaccine a week ago. The drug agency stated that the safety committee went to work immediately to evaluate the vaccine safety and efficacy for […]
Official: Why NAFDAC approved Oxford-AstraZeneca coronavirus vaccine
February 18, 2021
The National Agency for Food and Drug Administration and Control (NAFDAC) on Thursday approved Oxford AstraZeneca COVID-19 vaccine for use in Nigeria.
The Director-General of the agency, Prof. Mojisola Adeyeye, gave the go ahead for the use of the vaccine at a news conference in Abuja.
She said that the NAFDAC Vaccine Committee commenced expedited review immediately the agency received the Oxford AstraZeneca COVID-19 vaccine dossier from Serum Institute of India on Feb. 10.
She explained that members of the committee worked assiduously to review the vaccine as planned, noting that the recommendation for the emergency use authorisation was based on rigorous scientific consideration.